- Shopping Bag ( 0 items )
Doody's Review ServiceReviewer: Sara A Li, PhD (University of Kansas Medical Center)
Description: This monograph in the CRC Enzyme Inhibitors Series provides an excellent review of the current status in the development of cyclin-dependent kinases (CDK) inhibitors.
Purpose: The purpose is to review the current status of the development of CDK inhibitors.
Audience: Basic and clinical scientists interested in the development of new cancer therapies are the intended audience. The book will be particularly useful for scientists interested in translational research. The authors of the chapters are experts in their fields of research.
Features: The book is divided into four sections to allow readers to become familiar with possible targets of cell cycle inhibitions. The initial chapters provide an excellent background on the role of CDK in cell cycle control pathways and open the doors for the understanding of their potential use as therapeutic agents. The subsequent chapters review the use of mammalian systems, their selective inhibition, detailed description of their design, development, and chemistry. In addition, the book includes a summary of their current use in combination with other neoplastic agents and a perspective for their future use.
Assessment: This excellent monograph provides basic, clinical, and translational information on the potential use of CDK inhibitors as anti-tumor agents.